Sanera, s.r.o. Report issue

For profit Phase 3
Founded: Presov Slovakia (2010)

Organization Overview

First Clinical Trial
2015
NCT02609828
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Sanera, s.r.o. Neurologicka a algeziologicka ambulancia

Active Ingredients

Drugs in Phase 3 Trials (1)

tanezumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cancer Pain (Phase 3)

Musculoskeletal Pain (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1